|
Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204. |
|
Hussein Abdul-Hassan Tawbi |
Consulting or Advisory Role - Novartis |
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Novartis (Inst) |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Novocure; ZIOPHARM Oncology |
Travel, Accommodations, Expenses - Novocure |
|
|
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Oncosec (Inst) |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; Novartis; Roche |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Genentech; Novartis |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Genentech (Inst); Immunocore (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Rinat (Inst); Roche (Inst) |
|
|
Employment - Dana-Farber Cancer Institute |
Consulting or Advisory Role - Amgen; EMD Serono; Genentech/Roche; Merck Sharp & Dohme; Novartis |
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst) |
Patents, Royalties, Other Intellectual Property - patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis |
Other Relationship - Bristol-Myers Squibb; Genentech/Roche |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Castle Biosciences; EMD Serono |
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); GlaxoSmithKline; Merck (Inst); NCCN (Inst); Novartis (Inst); Pfizer (Inst); Threshold Pharmaceuticals (Inst); TRACON Pharma (Inst) |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Castle Biosciences; GlaxoSmithKline; Roche/Genentech |
Consulting or Advisory Role - Piramal Life Science; Roche |
Research Funding - Bristol-Myers Squibb; Castle Biosciences; GlaxoSmithKline; Merck; Roche/Genentech |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; Merck |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Novartis |
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Infinity Pharmaceuticals (Inst); Novartis (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
Honoraria - Bristol-Myers Squibb |
Consulting or Advisory Role - Alkermes; Amgen; Bristol-Myers Squibb; C-Cam; Genentech; Genoptix; GlaxoSmithKline; Infinity Pharmaceuticals; Lilly; Merck; Nektar; Novartis; Pfizer; X4 Pharma |
|
|
Stock and Other Ownership Interests - GE Healthcare |
Consulting or Advisory Role - Celyad; Omniseq |
Research Funding - Alkermes; Altor BioScience; Bristol-Myers Squibb; Merck |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Roche/Genentech |
Travel, Accommodations, Expenses - Amgen; Merck |
|
|
Honoraria - Bristol-Myers Squibb |
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis |
|
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Merck |
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Prometheus (Inst) |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
|
|
Consulting or Advisory Role - Inanovate; Lion Biotechnologies; Pfizer |
Research Funding - Altor Bioscience; Merck |